Cognitive disorders involve disturbances in information processing and integration associated with cognitive impairment and/or progressive cognitive decline.
Translational EEG biomarkers represent powerful means to measure procognitive or anti-psychotic treatments efficacy.
Our programs feature
- Expertise in developping models of cognitive impairment
- Selection of appropriate methods that translate into the clinic (Auditory-evoked potentials, pharmaco-induced models)
- Specific skills in analyzing complex data sets
- Personnalized support in selecting the best study design
Biomarkers: ASSR, ERPs, EROs, MMN, Gating, Multisite Coherence
Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), rodent model phenotyping
Please take a moment to read our article: Improving Early Decision-Making in Schizophrenia